Axsome Therapeutics, Inc. (AXSM) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in New York City, NY, United States. Der aktuelle CEO ist Herriot Tabuteau.
AXSM hat IPO-Datum 2015-11-19, 712 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Market, eine Marktkapitalisierung von $9.42B.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's lead candidate, AXS-05, is being evaluated for major depressive disorder, treatment-resistant depression, Alzheimer's disease agitation, and smoking cessation across Phase II and Phase III clinical trials. Its pipeline also includes AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all in late-stage development. Founded in 2012 and headquartered in New York, Axsome collaborates with leading institutions including Duke University to advance its clinical programs.
